Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis.
about
Association of a specific haplotype across the genes MMP1 and MMP3 with radiographic joint destruction in rheumatoid arthritisMatrix Metalloproteinases in Non-Neoplastic Disorders.Biochemical markers of ongoing joint damage in rheumatoid arthritis--current and future applications, limitations and opportunities.Early biomarkers of joint damage in rheumatoid and psoriatic arthritisSoluble biomarkers of cartilage and bone metabolism in early proof of concept trials in psoriatic arthritis: effects of adalimumab versus placeboMetalloproteinases and their inhibitors-diagnostic and therapeutic opportunities in orthopedics.The efficacy of shikonin on cartilage protection in a mouse model of rheumatoid arthritis.Matrix Metalloproteinase Gene Activation Resulting from Disordred Epigenetic Mechanisms in Rheumatoid Arthritis.Identification of urinary peptide biomarkers associated with rheumatoid arthritis.Serological biomarkers of joint tissue turnover predict tocilizumab response at baselineMatrix metalloproteinases and protein tyrosine kinases: potential novel targets in acute lung injury and ARDSLack of association of matrix metalloproteinase-3 gene polymorphism with susceptibility to rheumatoid arthritis: a meta-analysis.Matrix metalloproteinase-8 deficiency increases joint inflammation and bone erosion in the K/BxN serum-transfer arthritis model.Physiology and pathophysiology of matrix metalloproteases.Anti-arthritic activity of Fu-Fang-Lu-Jiao-Shuang on collagen-induced arthritis in Balb/c mice and its underlying mechanismsMatrix metalloproteinase 3 is a mediator of pulmonary fibrosis.Silica exposure is associated with increased risk of developing rheumatoid arthritis: results from the Swedish EIRA studyToll-like receptor 2 (TLR2) induces migration and invasive mechanisms in rheumatoid arthritis.Baseline serum MMP-3 levels in patients with Rheumatoid Arthritis are still independently predictive of radiographic progression in a longitudinal observational cohort at 8 years follow upProteinases in the joint: clinical relevance of proteinases in joint destructionRNA-seq analysis of synovial fibroblasts brings new insights into rheumatoid arthritis.Rational design of antirheumatic prodrugs specific for sites of inflammation.Serum matrix metalloproteinase-3 in comparison with acute phase proteins as a marker of disease activity and radiographic damage in early rheumatoid arthritis.Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITYInvolvement of angiopoietin-like 4 in matrix remodeling during chondrogenic differentiation of mesenchymal stem cells.The importance of matrix metalloproteinase-3 in respiratory disorders.Biomarkers of cartilage and surrounding joint tissue.Increased levels of the 14-3-3 η and γ proteins in the synovial fluid of dogs with unilateral cranial cruciate ligament rupture.Steroid therapy and renal dysfunction are independently associated with serum levels of matrix metalloproteinase-3 in patients with rheumatoid arthritis.Differential regulation of c-Met signaling pathways for synovial cell function.Synovial tissue research: a state-of-the-art review.Gene expression profile of LPS-stimulated dendritic cells induced by a recombinant Sj16 (rSj16) derived from Schistosoma japonicum.Combination effects of prednisolone and interleukin-4 protect bovine nasal cartilage explants from interleukin-1α induced degradation.Low prevalence of knee chondrocalcinosis and its catabolic association by use of serum matrix metalloproteinase 3: A rural Japanese population study.Influence of Matrix metalloproteinase 1 and 3 genetic variations on susceptibility and severity of juvenile idiopathic arthritis.Matrix metalloproteinase secretion by gastric epithelial cells is regulated by E prostaglandins and MAPKs.Protective effects of interleukin-4 on tissue destruction and morphological changes of bovine nasal chondrocytes in vitro.Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-alpha, Oncostatin M and response to biologic therapies.Ultrasonographic evaluation of femoral cartilage thickness in patients with ankylosing spondylitis.A matrix metalloproteinase 1-cleavable composite peptide derived from transforming growth factor β-inducible gene h3 potently inhibits collagen-induced arthritis.
P2860
Q24800622-F1871449-6F4C-4556-8716-CC04DA958542Q26741827-BF128EE6-1BBA-4538-8669-082FABE5F441Q27687777-7421BDA4-F500-4579-82FE-EF1046F96CDBQ28083506-EFBA15A0-8533-4553-A2FE-337079146A0CQ28475485-442A2714-0F49-46F5-92A1-AA108F01F15DQ33660754-E2684E0F-F349-4E4E-8277-6816B3E53450Q33688124-8A74875E-C791-4121-84F7-8EAE6BC20030Q33754764-4F1F8C65-77A3-4215-9772-2074D663289DQ34075303-3FF8FF81-BBA0-49E9-BDD4-EA2CA246C6B6Q34134566-74AA9F00-5EB5-47E2-9A03-E756C969223BQ34299797-E5FBA6A2-9798-4DFB-982A-A401D04D67CEQ34587358-CF664B17-91F3-42D6-8025-FBD83B3E90CCQ34614073-86E4EBF2-BB17-42B9-8D80-5F29CF1E5EBDQ35007715-FAF5CF19-0D91-4AD5-9A9D-C96A6E1757BCQ35228585-9CAF0232-0FB5-4EE5-A40F-AFB3B4DA0DBBQ35235706-7EB3A309-E386-4854-AA76-3CD5C675DEA8Q35555456-AA7DB1FB-E3DC-4B2F-9D84-0B9958F1F3D8Q35830873-692ACBEA-4E2D-4BBC-9869-DBEEAF77942DQ36085007-8841D464-B965-48C3-BCE1-F25166513D34Q36401848-F63B0979-7D94-46D0-AC5D-15BF08E014EDQ36575871-C47FFAE2-0520-4C54-BD1A-A47A96E5D680Q36799824-7C3483C2-D0E4-4364-A832-13821E0A9C18Q36830906-0E66B796-879C-4D99-B1C0-8D7C0093039DQ37315782-A4A99ED7-3551-41B5-AC34-96FDF356FD28Q37653289-E86A7EC0-A20A-4042-A658-B423F5CBF5C3Q38215534-5C4D7AED-11E8-4DDE-83AB-39AC9536035DQ38239828-91AA6BD9-F08C-470F-8DCF-D0A143489647Q38633068-26CEED73-58BC-4A66-83D8-AE5BA3101660Q38653180-3C89AD46-3FBF-49B0-86EF-13F7638FA7DEQ38946360-827BC9D8-E7AF-439F-A49D-A3DCB5DFDDAAQ39431367-F8685F7C-F5BA-4D9A-9B02-4C3D93D7BDDEQ39455171-7C58AFA3-9BD4-4D59-87AC-3C70AAF694F0Q39510799-41BCC8D6-643A-47E6-8B7C-70C83AB746E1Q40276227-27EFCD50-40A3-4624-A137-E8614A3C6958Q40383704-64E50D74-84A3-418A-AADE-36B85358CD3FQ40473467-640F8089-F500-4F22-90D8-194A726B1857Q41854783-194B7295-F469-4469-8411-ABDDF45BADF7Q42136310-A18A1725-D46D-403D-A99A-72EEEC775984Q42585556-6969CE53-C8C2-4796-8BC1-87E81E537254Q42824423-F19FD6F5-9891-4D2A-A0DE-19830E70811E
P2860
Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis.
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh-hant
name
Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis.
@en
Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis.
@en-gb
Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis.
@nl
type
label
Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis.
@en
Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis.
@en-gb
Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis.
@nl
prefLabel
Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis.
@en
Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis.
@en-gb
Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis.
@nl
P2093
P356
P1433
P1476
Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis.
@en
P2093
P356
10.1093/RHEUMATOLOGY/KEG037
P50
P577
2003-01-01T00:00:00Z
P6179
1034690293